Grapevine: Biocon, Shriram Finance plan to sell units; Footpath Ventures eyes IPL franchise

Premium

Biocon Ltd is considering a plan to sell its generic active pharmaceutical ingredient (API) business to lower its debt, a media report said.  The generic API business is worth around $1.5 billion, The Economic Times reported, citing people familiar with the matter.  The report said that Biocon has engaged in discussions with ......